fluvoxamine and Weight-Loss

The effect of fluvoxamine versus placebo on serum cholesterol levels in obese women undergoing behavior therapy for weight reduction was evaluated.. Forty obese female outpatients undergoing 13 weeks of a behaviorally oriented treatment program for weight reduction were randomly assigned to double-blind treatment with fluvoxamine 100 mg/day (N = 18) or placebo (N = 22). Total serum cholesterol levels were measured before and after the 13-week study period.. Patients of the two treatment groups did not differ in age, weight, body mass index, cholesterol levels before treatment, and the extent of weight reduction during treatment. Cholesterol levels were significantly lower after fluvoxamine treatment than before, whereas cholesterol levels remained unaltered after placebo administration. Patients with initially high total cholesterol levels (> or = 200 mg/dL) showed a significantly larger reduction than patients with desirable cholesterol levels. However, there was no interaction between treatment and initial cholesterol level.. The results might suggest a cholesterol-lowering effect of fluvoxamine.

Topics: Adult; Ambulatory Care; Behavior Therapy; Body Mass Index; Cholesterol; Comorbidity; Female; Fluvoxamine; Humans; Hypercholesterolemia; Middle Aged; Obesity; Regression Analysis; Weight Loss

Topics: Adult; Combined Modality Therapy; Comorbidity; Energy Intake; Enteral Nutrition; Family Therapy; Feeding and Eating Disorders; Fluvoxamine; Follow-Up Studies; Gastric Emptying; Humans; Individuation; Intellectual Disability; Internal-External Control; Life Change Events; Male; Patient Admission; Patient Compliance; Referral and Consultation; Weight Loss; Williams Syndrome

Topics: Adult; Desensitization, Psychologic; Ephedra; Eye Movements; Female; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Phytotherapy; Plant Preparations; Recurrence; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Weight Loss

Brain serotonin plays a crucial role in the regulation of food intake and body weight homeostasis. Previous data suggest an interaction with corticotropin-releasing hormone (CRH). To further examine the interaction between these neurotransmitters, the selective serotonin reuptake-inhibitor (SSRI) fluvoxamine was given intraperitoneally in fa/fa Zucker rats with and without the CRH-receptor-antagonist alpha-helical CRH administered intracerebroventricularly (i.c.v.). The saline treated animals gained weight. Fluvoxamine led to a significant weight loss while not affecting food intake. Furthermore, insulin levels in this animal model were reduced following fluvoxamine administration. These effects were antagonized by alpha-helical CRH and are thus most likely mediated via CRH or CRH-like peptides.

Topics: Animals; Body Weight; Corticotropin-Releasing Hormone; Eating; Fluvoxamine; Hormone Antagonists; Injections, Intraperitoneal; Male; Rats; Rats, Zucker; Selective Serotonin Reuptake Inhibitors; Weight Loss

The results of a small pilot study using Fluvoxamine (Faverin) in the treatment of non-vomiting bingeing female patients and women with bulimia nervosa is presented. Ten non-vomiting subjects and six with bulimia nervosa were treated on an open basis with Fluvoxamine 100-200 mg daily. Assessment was made using established questionnaires for severity of eating disorder and abnormality of mood. Five non-vomiting patients and three with bulimia nervosa completed the study. Non-vomiters showed a significant weight loss; a significant reduction in number of binges; a significant reduction in the scores on the BITE and the EAT; and a significant reduction in anxiety. Those with bulimia nervosa had a significant reduction in hunger and a reduction in depression which tended towards significance. Firm conclusions cannot be drawn from this study as it is an open pilot study of a small number of women. However, the results indicate that Fluvoxamine may have a role in the treatment of eating disorders where bingeing is a prominent symptom and that further research would be valuable. Comments are also made on the usefulness of various questionnaires designed to assess eating disorders.

Topics: Adolescent; Adult; Bulimia; Depression; Feeding and Eating Disorders; Female; Fluvoxamine; Humans; Obesity; Surveys and Questionnaires; Vomiting; Weight Loss

Topics: Depressive Disorder; Energy Metabolism; Female; Fluvoxamine; Humans; Middle Aged; Oximes; Weight Loss